Overview

Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML

Status:
Not yet recruiting

Trial end date:
2028-09-01

Target enrollment:

Participant gender:

Summary

This phase II clinical trial evaluates the efficacy and tolerability of the non-intensive treatment with venetoclax and the hypomethylating agent azacitidine as compared to the standard of care chemotherapy plus gemtuzumab ozogamicin in newly diagnosed NPM1 mutated AML patients fit for intensive chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Technische Universität Dresden

Collaborators:

AbbVie
University Hospital Heidelberg

Treatments:

Azacitidine
Gemtuzumab
Venetoclax